1-3 of 3
Daniel Yoo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera.

Min Lu, PhD, Wei Zhang, Daniel Yoo, Dmitriy Berenzon, Yan Li, Xiaoli Wang, MD, PhD, Adam Austin, John Mascarenhas, MD, Mingjiang Xu, MD, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2009) 114 (22): 3916.
https://doi.org/10.1182/blood.V114.22.3916.3916
Published: 2009
Journal Articles

Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells.

Min Lu, PhD, Wei Zhang, Jiapeng Wang, Yan Li, Xiaoli Wang, MD, PhD, Daniel Yoo, Adam Austin, John Mascarenhas, MD, Zhizhuang Joe Zhao, Ronald Hoffman, MD, Mingjiang Xu, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 752.
https://doi.org/10.1182/blood.V114.22.752.752
Published: 2009
Journal Articles

Sequential Treatment of CD34 + Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells.

Xiaoli Wang, MD, PhD, Wei Zhang, Adam Austin, Daniel Yoo, Min Lu, Mingjiang Xu, MD, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2009) 114 (22): 1910.
https://doi.org/10.1182/blood.V114.22.1910.1910
Published: 2009